Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients with newly diagnosed type-1 diabetes mellitus (T1DM)
• To assess the effect of ACZ885, in addition to standard of care, on the area under the curve of the stimulated C peptide after a mixed meal tolerance test conducted after 12 months’ treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg once daily versus open label tiotropium 18 μg once daily in patients with moderate to severe chronic obstructive pulmonary disease
To demonstrate superiority of indacaterol 150 µg o.d. in combination with tiotropium 18 µg o.d. versus tiotropium 18 µg o.d. with respect to standardized AUC for FEV1 between 5 min – 8 h post-dose aft...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 4 ans
A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis
to demonstrate that the percent change in lumbar spine BMD at Month 12 relative to baseline in male and female patients treated with one iv zoledronic acid 5 mg dose at randomization is not inferior ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals
Update Il y a 4 ans
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
To assess the long-term safety and tolerability of omalizumab by measuring AEs, serious AEs, physical examination, medical history, laboratory assessments and vital signs
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib compared to two placebos (inactive drugs) in the treatment of BRAF V600E/K mutation-positive melanoma after surgery
To evaluate the efficacy of dabrafenib and trametinib combination therapy compared to two placebos with respect to relapse-free survival (RFS) in patients with completely resected, histologically conf...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose versus MMF with standard Neoral® dose in de novo heart transplant recipients
•To demonstrate that comparable (non-inferior) renal function (calculated creatinine clearance according to Cockroft-Gault) is achieved in cohorts of de novo heart recipients treated with Certican/red...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Safety and Efficacy of QAX576 in Patients With Progressive Idiopathic Pulmonary Fibrosis (IPF)
• To evaluate the safety and tolerability of multiple intravenous dosing of QAX576 in patients with IPF • To evaluate the effect of multiple intravenous dosing of QAX576 on lung function assessed b...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to a 4 week therapy with candesartan 32 mg plus hydrochlorothiazide 25 mg
To demonstrate that 4 weeks of treatment with aliskiren 300mg plus hydrochlorothiazide 25mg in combination provide an additional mean sitting diastolic blood pressure reduction in hypertensive patient...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthma
To assess the bronchodilator effect of orally inhaled indacaterol salts (maleate, xinafoate and acetate) in patients with persistent asthma compared with placebo as measured by mean change in FEV1 fro...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next